Resurrecting the discussion on neurotoxicity of lithium at therapeutic levels.

abstract：:Several cardiovascular risk factors have been linked to antipsychotic treatment and cardiovascular mortality is increased in these patients compared to the general population. The full metabolic syndrome (or its components) is associated with an increased risk of cardiovascular disorders. The prevalence of the metabol...

journal_title：International clinical psychopharmacology

authors： Hägg S,Lindblom Y,Mjörndal T,Adolfsson R

更新日期：2006-03-01 00:00:00

abstract：:This study is aimed at investigating the efficacy and tolerability of mirtazapine in a generalized social anxiety disorder. Sixty patients with generalized social anxiety disorder were randomly allocated to receive mirtazapine (30-45 mg/day) (n= 30) or placebo (n= 30) for 12 weeks in a double-blind study design. Prima...

journal_title：International clinical psychopharmacology

authors： Schutters SI,Van Megen HJ,Van Veen JF,Denys DA,Westenberg HG

更新日期：2010-09-01 00:00:00

abstract：:The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. T...

journal_title：International clinical psychopharmacology

authors： Golubchik P,Rapaport M,Weizman A

更新日期：2017-09-01 00:00:00

abstract：:Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...

journal_title：International clinical psychopharmacology

authors： Berk M,Ichim L,Brook S

更新日期：1999-11-01 00:00:00

abstract：:The effect of adjunctive fluoxetine on negative schizophrenic symptoms was evaluated in 34 chronic schizophrenic in-patients on maintenance therapy with neuroleptics. They received randomly, on a double-blind basis, fluoxetine (20 mg/day) or placebo for 12 weeks. In the fluoxetine group, three patients dropped out bec...

journal_title：International clinical psychopharmacology

authors： Spina E,De Domenico P,Ruello C,Longobardo N,Gitto C,Ancione M,Di Rosa AE,Caputi AP

更新日期：1994-01-01 00:00:00

abstract：:Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient. Polysomnographic investigation showed a low level of sleep efficacy, periodic leg movements, and a strict relationship betwe...

journal_title：International clinical psychopharmacology

authors： Horiguchi J,Yamashita H,Mizuno S,Kuramoto Y,Kagaya A,Yamawaki S,Inami Y

更新日期：1999-01-01 00:00:00

abstract：:The negative symptoms of schizophrenia remain a major clinical challenge. Reboxetine is an antidepressant whose major mechanism of action is as a noradrenergic reuptake inhibitor. This study was a 6-week randomized placebo-controlled trial of reboxetine or placebo add on to haloperidol 5 mg in the treatment of 30 pati...

journal_title：International clinical psychopharmacology

authors： Schutz G,Berk M

更新日期：2001-09-01 00:00:00

abstract：:Systematic information about Latino clozapine users is still scarce. Our aim was to evaluate the risk of clozapine-associated neutropenia in a Chilean cohort using the last Food and Drug Administration's recommendations for clozapine monitoring. Findings should improve clinical practice and promote changes in clozapin...

journal_title：International clinical psychopharmacology

authors： Mena CI,Nachar RA,Crossley NA,González-Valderrama AA

更新日期：2019-09-01 00:00:00

abstract：:Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

journal_title：International clinical psychopharmacology

authors： Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

更新日期：1996-06-01 00:00:00

abstract：:Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

journal_title：International clinical psychopharmacology

authors： Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

更新日期：2014-03-01 00:00:00

abstract：:The treatment of depressed patients with a fixed dose of amitriptyline is compared to treatment with an individualized dose calculated by means of a simple pharmacokinetic test. Clinical response and the development of side-effects are compared between the two groups of patients. Although the numbers in the groups wer...

journal_title：International clinical psychopharmacology

authors： Roy D,Dawling S

更新日期：1987-10-01 00:00:00

abstract：:Using spectral analysis of heart rate, several studies have shown that panic disorder patients are characterized by a reduced heart rate variability (HRV), indicative of abnormalities in autonomous nervous system (ANS) function. We recently reported that patients with panic disorder, who did not respond to pharmacothe...

journal_title：International clinical psychopharmacology

authors： Slaap BR,Boshuisen ML,van Roon AM,den Boer JA

更新日期：2002-03-01 00:00:00

abstract：:This double-blind study was performed on 10 aged insomniac patients who received, during 15 days, either triazolam (0.25 mg) or zopiclone (7.5 mg) at bed time. This in-patient period was bounded by two ambulatory periods of 5 days each, and two in-patient periods of 3 days each, during which the patients received a pl...

journal_title：International clinical psychopharmacology

authors： Mouret J,Ruel D,Maillard F,Bianchi M

更新日期：1990-04-01 00:00:00

abstract：:Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

journal_title：International clinical psychopharmacology

authors： Joyce PR

更新日期：1988-04-01 00:00:00

abstract：:The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...

journal_title：International clinical psychopharmacology

authors： Seeman P

更新日期：1995-09-01 00:00:00

abstract：:Depressive symptoms are associated with poor outcomes, increased risk of relapse, and high suicide rates in patients with schizophrenia and schizoaffective disorder. This randomized, open-label, parallel-group, flexible-dose study (NCT00640562) assessed the efficacy of quetiapine extended release (XR) versus risperido...

journal_title：International clinical psychopharmacology

authors： Di Fiorino M,Montagnani G,Trespi G,Kasper S

更新日期：2014-05-01 00:00:00

abstract：:Sixteen young male volunteers received single doses of moclobemide 200 mg, moclobemide 400 mg, amitriptyline 50 mg and placebo in a double-blind crossover study. Subjects then completed a test battery which is sensitive to the effects of psychoactive drugs at 1, 2, and 4 h post-dose. The test battery included tasks of...

journal_title：International clinical psychopharmacology

authors： Fairweather DB,Kerr JS,Hindmarch I

更新日期：1993-04-01 00:00:00

abstract：:Medication adherence with antipsychotics is adversely impacted by the burden of untoward adverse effects. In particular, sexual side-effects may interfere with compliance, but are often underreported by patients. Sexual dysfunction related to hyperprolactinemia is commonly described, but ejaculatory disturbance due to...

journal_title：International clinical psychopharmacology

authors： Loh C,Leckband SG,Meyer JM,Turner E

更新日期：2004-03-01 00:00:00

abstract：:Twelve normal weight healthy male volunteers participated in a double-blind, placebo-controlled trial of the effects of d- and l-fenfluramine, d-amphetamine, and the interactions between the two isomers of fenfluramine with amphetamine, on cortisol secretion. d-Fenfluramine and d-amphetamine in combination produced th...

journal_title：International clinical psychopharmacology

authors： Feeney S,Goodall E,Silverstone T

更新日期：1993-10-01 00:00:00

abstract：:C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

journal_title：International clinical psychopharmacology

authors： Kim SH,Reaven G,Lindley S

更新日期：2011-01-01 00:00:00

abstract：:Severe orthostatic and cardiorespiratory dysregulation may occur during institution of clozapine therapy both during concomitant benzodiazepine medication and on reinstitution of clozapine after a washout period. Extensive medical and neurological workup before and after the trials can nevertheless be normal. The abse...

journal_title：International clinical psychopharmacology

authors： Bredbacka PE,Paukkala E,Kinnunen E,Koponen H

更新日期：1993-10-01 00:00:00

abstract：:Obsessive-compulsive disorder (OCD) has emerged as a common but frequently hidden psychiatric disorder which inflicts an intolerable burden on sufferers and demands effective management. For many years, however, OCD was considered treatment resistant and it is only in the past 15 years that effective therapy has becom...

journal_title：International clinical psychopharmacology

authors： Fineberg N

更新日期：1996-12-01 00:00:00

abstract：:Negative symptoms are a key feature of schizophrenia. Novel (atypical) antipsychotic drugs, unlike conventional antipsychotics, cause substantial reductions in Positive and Negative Symptom Scale (PANSS) scores. Negative symptoms, however, can arise from both the pathology of the disease (primary negative symptoms) an...

journal_title：International clinical psychopharmacology

authors： Möller HJ

更新日期：1998-03-01 00:00:00

abstract：:"Agitation" is a term that is used to describe a wide range of dysfunctional behaviours in geriatric populations. The term is so widely used that in many cases it loses clinical meaning and therefore a more restricted use of the term is suggested. When patients with agitation are identified it is important to look for...

journal_title：International clinical psychopharmacology

authors： Ancill RJ,Carlyle WW,Liang RA,Holliday SG

更新日期：1991-01-01 00:00:00

abstract：:The aim of this study was to investigate the prevalence of benzodiazepine and related drug (BZDR) use, especially long-term use, and associated factors among community-dwelling individuals with and without Alzheimer's disease (AD). We utilized data from the MEDALZ-2005 cohort, which includes all community-dwelling ind...

journal_title：International clinical psychopharmacology

authors： Taipale H,Koponen M,Tanskanen A,Tolppanen AM,Tiihonen J,Hartikainen S

更新日期：2015-07-01 00:00:00

abstract：:Sertindole is a novel atypical antipsychotic, which has shown efficacy in the treatment of positive and negative symptoms of schizophrenia in phase II and III studies. Furthermore, these studies have demonstrated tolerability and a favourable side-effect profile. In contrast to classical antipsychotics, sertindole was...

journal_title：International clinical psychopharmacology

authors： Pezawas L,Quiner S,Moertl D,Tauscher J,Barnas C,Küfferle B,Wolf R,Kasper S

更新日期：2000-07-01 00:00:00

abstract：:The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...

journal_title：International clinical psychopharmacology

authors： Zhang XY,Zhou DF,Cao LY,Zhang PY,Wu GY,Shen YC

更新日期：2001-11-01 00:00:00

abstract：:Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...

journal_title：International clinical psychopharmacology

authors： Dahl AA

更新日期：1996-06-01 00:00:00

abstract：:We aimed to construct and assess the psychometric properties of the My Medicines and Me Questionnaire (M3Q), a self-report side-effect questionnaire for mental health patients. Thirty individuals taking a psychotropic medication completed the M3Q side-effect checklist along with the Liverpool University Neuroleptic Si...

journal_title：International clinical psychopharmacology

authors： Ashoorian DM,Davidson RM,Rock DJ,Dragovic M,Clifford RM

更新日期：2015-07-01 00:00:00

abstract：:We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...

journal_title：International clinical psychopharmacology

authors： Velayudhan L,Kirchner V

更新日期：2005-03-01 00:00:00